GlassScriptPhysician profile
George Michael Northrup
NPI 1629006507
$8,178.14
in general payments reported to CMS, 2019-2025
26 companies · $908 in 2025
The $908 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $475 · 2020: $3,346 · 2021: $384 · 2022: $363 · 2023: $1,406 · 2024: $1,297 · 2025: $908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,596 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,595.56 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $4,227.47 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $808.79 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $431.25 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Alkermes, INC. | $265.77 | 2023-2024 | Lybalvi, Aristada, Vivitrol |
| Neurocrine Biosciences, INC. | $252.50 | 2024-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $209.69 | 2024-2025 | Auvelity |
| Almatica Pharma LLC | $203.37 | 2023-2024 | Gralise, Loreev Xr |
| Vanda Pharmaceuticals INC. | $198.54 | 2023-2025 | Hetlioz, Fanapt |
| Livanova USA, INC. | $189.63 | 2021 | |
| Bausch Health US, LLC | $185.78 | 2019-2025 | Aplenzin, Wellbutrin |
| Teva Pharmaceuticals USA, INC. | $180.62 | 2023 | Austedo Xr |
| Indivior INC. | $174.39 | 2019-2025 | Sublocade |
| Allergan, INC. | $135.09 | 2019 | |
| Noven Therapeutics, LLC | $135.06 | 2023-2025 | Xelstrym, Secuado |
| Neos Therapeutics, LP | $82.80 | 2019-2023 | Adzenys Xr-Odt |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainsway USA INC | $73.68 | 2023 | |
| Lundbeck LLC | $73.42 | 2019-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $57.86 | 2023-2025 | Trintellix |
| Avanir Pharmaceuticals, INC. | $57.82 | 2019-2020 | |
| Braeburn INC. | $47.54 | 2024-2025 | Brixadi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.92 | 2023-2025 | Caplyta |
| Boston Scientific Corporation | $41.45 | 2024 | Apollo Esg Nxt System |
| E.R. Squibb & Sons, L.L.C. | $41.36 | 2025 | Cobenfy |
| Sage Therapeutics, LLC | $28.08 | 2024 | |
| Supernus Pharmaceuticals, INC. | $19.29 | 2023 | Qelbree |
| Adlon Therapeutics L.P. | $14.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Northrup listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.